These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 31602831)

  • 1. [Technical specifications for hospital-based intensive monitoring of post-marketing Chinese patent medicine].
    Xie YM; Liao X; Jiang JJ; Zhang YL; Ma R; Zhu MJ; Zhan SY; Liu JP; Liu J; Wen ZH; Yang ZQ; He Y; Li XL
    Zhongguo Zhong Yao Za Zhi; 2019 Jul; 44(14):2896-2901. PubMed ID: 31602831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guidelines for economic evaluation of post-marketing Chinese patent medicine].
    Shi LW; Xie YM; Nie XY; Han S; Tian X; Wang ZF
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(4):1129-1136. PubMed ID: 38621920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Exploration of how to formulate guidelines on post-marketing traditional Chinese medicine surveillance].
    Zhang W; Xie YM; Yu WY
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2943-8. PubMed ID: 24471309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Explore method about post-marketing safety re-evaluation of Chinese patent medicines based on HIS database in real world].
    Yang W; Xie Y; Zhuang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2779-82. PubMed ID: 22292363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Guidelines for post-marketing research on clinical effectiveness of Chinese patent medicines].
    Wang ZF; Xie YM; Tang JY; Zhang JH; Sun X; Yang ZQ
    Zhongguo Zhong Yao Za Zhi; 2024 Feb; 49(3):842-848. PubMed ID: 38621888
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Core elements of safety monitoring report of medicines(Chinese patent medicines)].
    Wang GQ; Liao X; Xie YM
    Zhongguo Zhong Yao Za Zhi; 2016 Dec; 41(24):4483-4487. PubMed ID: 28936827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Technical specifications for intensive hospital safety monitoring of post-marketing Chinese medicine (draft version for comments)].
    Xie YM; Liao X; Zhao YB; Li MQ; Zhang YL; Ma R; Xian SX; Liu J; Li SY; Wen ZH; Yang ZQ; Zou JD; Sun HS; He Y; Li XL; Jiang JJ; Wang ZF; Li YY; Wang LX; Chang YP; Yang W; Zhang W
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2919-24. PubMed ID: 24471304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Technical specifications for post-marketing pharmacoeconomic evaluation of Chinese medicine (draft version for comments)].
    Xie YM; Wang X; Wang N; Chang YP
    Zhongguo Zhong Yao Za Zhi; 2013 Sep; 38(18):2925-9. PubMed ID: 24471305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Post-marketing re-evaluation about usage and dosage of Chinese medicine based on human population pharmacokinetics].
    Jiang J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2811-2. PubMed ID: 22292372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To establish a body of evidence on safety for postmarketing Chinese medicine: A new research paradigm.
    Liao X; Xie YM; Robinson N; Wang YY
    Chin J Integr Med; 2017 Mar; 23(3):226-232. PubMed ID: 27900605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Construction and practice on rational medication model of Chinese patent medicine for orthopedics based on ″symdrome-dosage-toxicity differentiation″ theory].
    Wang YG; Jin R; Qiang SS; Lin ZJ; Li HY; Lu S; Kong XW
    Zhongguo Zhong Yao Za Zhi; 2016 Jan; 41(2):350-353. PubMed ID: 28861985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Thinking on risk assessment and risk management of post-marketing Chinese medicine].
    Yu X; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2012 Jan; 37(2):262-4. PubMed ID: 22737865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Expert consensus on the design and implementation of clinical safety centralized monitoring study of Chinese medical injection].
    Zhang JH; Ren JT; Hu JQ; Xie YM; Song HB; Zhu MJ; Gao R; Wang Z; Zheng WK; Li XL; Jiang M; Huang YH; Lu F; He LY; Lian WX; Yang ZQ; Yuan WA; Hu SY; Wang BH; Wang WL; Ren DQ; Zhang BL; ;
    Zhongguo Zhong Yao Za Zhi; 2017 Jan; 42(1):6-9. PubMed ID: 28945018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Establish research model of post-marketing clinical safety evaluation for Chinese patent medicine].
    Zheng WK; Liu Z; Lei X; Tian R; Zheng R; Li N; Ren JT; Du XX; Shang HC
    Zhongguo Zhong Yao Za Zhi; 2015 Sep; 40(18):3693-6. PubMed ID: 26983223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Enlightenment of adverse reaction monitoring on safety evaluation of traditional Chinese medicines].
    Song HB; Du XX; Ren JT; Yang L; Guo XX; Pang Y
    Zhongguo Zhong Yao Za Zhi; 2015 Apr; 40(8):1620-3. PubMed ID: 26281610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Analysis and reflection on current situation of Chinese patent medicine for children in China].
    Liu H; Chen YJ; Fu QF; Zhao SY; Nie LH; Ma R; Rong P
    Zhongguo Zhong Yao Za Zhi; 2024 Apr; 49(7):1966-1973. PubMed ID: 38812209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-marketing safety monitoring of shenqifuzheng injection: a solution made of dangshen (Radix Codonopsis) and huangqi (Radix Astragali Mongolici).
    Ai Q; Zhang W; Xie Y; Huang W; Liang H; Cao H
    J Tradit Chin Med; 2014 Aug; 34(4):498-503. PubMed ID: 25185371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Study on building index system of risk assessment of post-marketing Chinese patent medicine based on AHP-fuzzy neural network].
    Li Y; Xie Y; Fu Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2828-30. PubMed ID: 22292377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Registration and review of Chinese patent drugs in Kunming and the compilation and revision of the
    Yang ZQ
    Zhonghua Yi Shi Za Zhi; 2017 Jul; 47(4):213-221. PubMed ID: 28954363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.